Navigation Links
Nile Therapeutics to Transition to OTCQB Marketplace
Date:5/11/2011

and reporting with the Securities and Exchange Commission. The Company expects its common stock will continue to trade under the "NLTX" symbol on the computerized OTCQB system. Investors will be able to view Level II Real Time stock quotes for Nile at http://www.otcmarkets.com.

About Nile Therapeutics

Nile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's transition from The Nasdaq Capital Market to the OTCQB Marketplace, including the timing of trading of and the prospects for a market developing for Nile's securities on the OTCQB, are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development program
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
2. InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries
3. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Cell Therapeutics Retires 7.5% Convertible Senior Notes
6. Talecris Biotherapeutics Announces First Quarter 2011 Results
7. Nektar Therapeutics Reports First Quarter 2011 Financial Results
8. Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics
9. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
10. Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
11. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014 One of the major ... personalized medicine, which is the practice of using genomic ... a patient,s individual biology. Personalized diagnostics—laboratory analyses that inform ... in the lab,s future. This fall, AACC ,s ... latest science in this exciting field and the novel ...
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... MARKETS , that the global market RNA interference (RNAi) ... $38.8 billion by 2018, with a five-year compound annual ... the fastest moving segment of the market, is moving ... RNAi therapeutics has shown tremendous growth and has moved ...
(Date:7/31/2014)... (PRWEB) August 01, 2014 ... China Polyurethane Resin Industry” is a professional ... market. The report introduces Polyurethane Resin basic ... industry chain structure and industry overview. This ... China’s domestic market as well as global ...
(Date:7/31/2014)... see through organs and even the entire body to ... cellular structures has been a long-time dream of biologists. ... 31st in the journal Cell has now ... making opaque organs, bodies, and human tissue biopsies transparent, ... protocols could pave the way for a better understanding ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4See-through organs and bodies will accelerate biomedical discoveries 2
... , SAN FRANCISCO, Aug. 11 ... stage biopharmaceutical company developing a proprietary breakthrough class of targeted ... private placement financing with gross proceeds of US $5,123,521, exceeding ... anticipated on or before September 15, 2009, with additional proceeds ...
... , , CAMBRIDGE, Mass., Aug. 11 ... of novel therapies for immune-mediated diseases, today announced changes to the protocol ... and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with ... ( D urable Response Therapy E valuation F or ...
... SEATTLE, Aug. 11 Omeros Corporation today announced ... OMS302, the Company,s ophthalmologic PharmacoSurgery(TM) product candidate. OMS302 is ... agent that causes pupil dilation (mydriasis), each with well-known ... Omeros, Phase 1/Phase 2 trial enrolled 61 patients undergoing ...
Cached Biology Technology:Jennerex Closes $5 Million First Tranche of Series C Financing 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 3Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery 2
(Date:7/31/2014)... enormous conflagration known as the Rim Fire was in ... mature trees, when it entered the backcountry of Yosemite ... 2013. But inside the park, the battle began to ... decisions and drought can combine to fuel large, severe ... it eventually encountered lands where fire had been used ...
(Date:7/31/2014)... are familiar with Hibiscus flowers- they are an ... are commonly planted in the landscape. Some, like ... endangered species. , Only a relatively few botanists ... an equally beautiful and intriguing related group of ... of Hibiscus". , Brother of Hibiscus species are ...
(Date:7/31/2014)... White, brown and beige adipocytes, or fat cells, are ... functions and each plays its own role in metabolism. ... far the most prevalent. Its primary function is energy ... energy to generate heat but are only found in ... adipocytes, which represent a special type of brown adipocytes, ...
Breaking Biology News(10 mins):The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5Brother of Hibiscus is found alive and well on Maui 2Hope for the overweight 2
... Washington, DC Engineered nanoscale materials (ENMs), which ... use in food packaging, raise new safety evaluation ... report released today by the Project on Emerging ... The food-packaging industry, food companies and ...
... developed an effective technology for reducing contamination of dangerous ... Salmonella and E. coli O157:H7 on foods ranging from ... It is made from inexpensive and readily available ingredients ... and Drug Administration. The new technology, which ...
... Almost every June for 30 years, Terry McEneaney drove around ... three routes. Park ornithologist at the time, he would ... Then he,d drive another half mile, repeat the process and ... for the North American Breeding Bird Survey. Trying to finish ...
Cached Biology News:Use of nanomaterials in food packaging poses regulatory challenges 2New UGA invention effectively kills foodborne pathogens in minutes 2Bird watchers, space technology come together in Montana State University study 2Bird watchers, space technology come together in Montana State University study 3
Recombinant Rhesus Macaque IFN-alpha...
chk 1 kinase...
...
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: